# Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori

> **NCT03108287** · PHASE4 · COMPLETED · sponsor: **Kaohsiung Medical University Chung-Ho Memorial Hospital** · enrollment: 162 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** RAK therapy
- **DRUG:** RBAK therapy

## Key facts

- **NCT ID:** NCT03108287
- **Lead sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-01
- **Primary completion:** 2015-01-31
- **Final completion:** 2015-02-28
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03108287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03108287, "Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03108287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*